Its biosimilar of Roche’s cancer and autoimmune disease drug MabThera (rituximab) is already on sale in Germany under the brand name Truxima. But the South Korean company has received the go ...
The results of two controlled trials, now published in the January 2010 issue of Arthritis and Rheumatism, suggest that treatment with the B-cell depleting agent, rituximab, lowers the response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback